Treatment Outcomes in People with Migraine Receiving Rimegepant or Triptans: A Descriptive Analysis from a Real-World Survey (P1-12.008)
Authors
- Sophie Barlow (ORCID: https://orcid.org/0000-0001-5604-1360)
- Karin Hygge Blakeman (ORCID: https://orcid.org/0000-0001-6925-7099)
- Joshua David Brown (ORCID: https://orcid.org/0000-0002-2973-1021)
- Lucy Abraham (ORCID: https://orcid.org/0000-0003-1648-8621)
- Feng Dai (ORCID: https://orcid.org/0000-0002-9963-6863)
- James Jackson (ORCID: https://orcid.org/0000-0002-4171-5390)
- Louise Hancock
- William Whitton (ORCID: https://orcid.org/0009-0004-8342-2125)
Institutions
- Pfizer (United States) (US)
- Pfizer (United Kingdom) (GB)
- Adelphi Group (United Kingdom) (GB)
- Pfizer (Sweden) (SE)